MedTrace Logo

In Vivo Succinate Detection After External Beam Radiation Therapy in SDHx- Paragangliomas

NCT04583384 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-12-22

No results posted yet for this study

Summary

Qualitative and quantitative biomarker of response to radiotherapy is needed in paragangliomas. We aim at assessing the added value of 1H-SRM for the evaluation of early response to EBR therapy in patients with cervical SDHx PGL.

Conditions

  • Paraganglioma of Head and Neck

Interventions

DIAGNOSTIC_TEST

1H-Spectroscopy MRI

PRESS asymetric monovoxel " PROBE ", TE 144 ms, TR 2500 ms, 768 or 1024 averages

Sponsors & Collaborators

  • Society for Endocrinology

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Laurence AMAR, PhD · Hôpital Européen Georges-Pompidou

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2022-06-30
Completion
2025-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04583384 on ClinicalTrials.gov